Codex_V5

Mutant	Gene	Type	Virus	EC50 ratio	Phenotype	Assay	Reference
D12E	UL51	SNP	Human betaherpesvirus 5	1.40	No resistance	Details	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
E17del	UL51	in/del	Human betaherpesvirus 5	1.30	No resistance	Details	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
P91S	UL51	SNP	Human betaherpesvirus 5	2.10	Low level resistance	Details	A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
A95V	UL51	SNP	Human betaherpesvirus 5	13.80	High level resistance	Details	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
V113L	UL51	SNP	Human betaherpesvirus 5	1.50	No resistance	Details	First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022)
C25F	UL56	SNP	Human betaherpesvirus 5	5.40	High level resistance	Details	New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
S229F	UL56	SNP	Human betaherpesvirus 5	1.80	No resistance	Details	A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
S229Y	UL56	SNP	Human betaherpesvirus 5	2.00	Low level resistance	Details	Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
V231A	UL56	SNP	Human betaherpesvirus 5	2.10	Low level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
V231L	UL56	SNP	Human betaherpesvirus 5	5.00	High level resistance	Details	Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
V231L	UL56	SNP	Human betaherpesvirus 5	8.90	High level resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
V231L	UL56	SNP	Human betaherpesvirus 5	8.10	High level resistance	Details	Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
N232Y	UL56	SNP	Human betaherpesvirus 5	17.00	High level resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
Q234R	UL56	SNP	Human betaherpesvirus 5	2.00	Low level resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
V236A	UL56	SNP	Human betaherpesvirus 5	2.90	Low level resistance	Details	New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
V236L	UL56	SNP	Human betaherpesvirus 5	14.00	High level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
V236M	UL56	SNP	Human betaherpesvirus 5	45.00	High level resistance	Details	Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
E237D	UL56	SNP	Human betaherpesvirus 5	10.00	High level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
L241P	UL56	SNP	Human betaherpesvirus 5	218.00	High level resistance	Details	Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
L243P	UL56	SNP	Human betaherpesvirus 5	1.00	No resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
T244K	UL56	SNP	Human betaherpesvirus 5	3.30	Intermediate level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
L254F	UL56	SNP	Human betaherpesvirus 5	3.20	Intermediate level resistance	Details	A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
L257F	UL56	SNP	Human betaherpesvirus 5	8.60	High level resistance	Details	A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
L257I	UL56	SNP	Human betaherpesvirus 5	4.90	Intermediate level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
K258E	UL56	SNP	Human betaherpesvirus 5	14.00	High level resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
F261C	UL56	SNP	Human betaherpesvirus 5	4.40	Intermediate level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
F261L	UL56	SNP	Human betaherpesvirus 5	2.80	Low level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
S262C	UL56	SNP	Human betaherpesvirus 5	1.00	No resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
Y321C	UL56	SNP	Human betaherpesvirus 5	4.60	Intermediate level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
C325F	UL56	SNP	Human betaherpesvirus 5	3000.00	High level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
C325R	UL56	SNP	Human betaherpesvirus 5	3000.00	High level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
C325Y	UL56	SNP	Human betaherpesvirus 5	8796.00	High level resistance	Details	Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
C325W	UL56	SNP	Human betaherpesvirus 5	9300.00	High level resistance	Details	New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
L328V	UL56	SNP	Human betaherpesvirus 5	1.90	No resistance	Details	New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
L328I	UL56	SNP	Human betaherpesvirus 5	1.40	No resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
M329T	UL56	SNP	Human betaherpesvirus 5	4.40	Intermediate level resistance	Details	Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
M329I	UL56	SNP	Human betaherpesvirus 5	0.77	No resistance	Details	Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
H335Y	UL56	SNP	Human betaherpesvirus 5	0.80	No resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
E339G	UL56	SNP	Human betaherpesvirus 5	1.20	No resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
F345L	UL56	SNP	Human betaherpesvirus 5	0.95-1.03	Range of values of No resistance	Details	Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
K350R	UL56	SNP	Human betaherpesvirus 5	1.10	No resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
V363I	UL56	SNP	Human betaherpesvirus 5	3.70	Intermediate level resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
A365S	UL56	SNP	Human betaherpesvirus 5	2.00	Low level resistance	Details	New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
N368D	UL56	SNP	Human betaherpesvirus 5	2.00	Low level resistance	Details	A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
N368I	UL56	SNP	Human betaherpesvirus 5	1.30	No resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
R369T	UL56	SNP	Human betaherpesvirus 5	52.00	High level resistance	Details	Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Mar 2020)
R369G	UL56	SNP	Human betaherpesvirus 5	44.00	High level resistance	Details	Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
R369M	UL56	SNP	Human betaherpesvirus 5	13.00	High level resistance	Details	Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
R369S	UL56	SNP	Human betaherpesvirus 5	48.00	High level resistance	Details	Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
R369K	UL56	SNP	Human betaherpesvirus 5	4.90	Intermediate level resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
R396S	UL56	SNP	Human betaherpesvirus 5	81.00	High level resistance	Details	Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
T399I	UL56	SNP	Human betaherpesvirus 5	0.80	No resistance	Details	Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
N320H	UL89	SNP	Human betaherpesvirus 5	1.80	No resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
N329S	UL89	SNP	Human betaherpesvirus 5	2.00	Low level resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
D344E	UL89	SNP	Human betaherpesvirus 5	1.80	No resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
T350M	UL89	SNP	Human betaherpesvirus 5	2.80	Low level resistance	Details	Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
M359I	UL89	SNP	Human betaherpesvirus 5	1.50	No resistance	Details	Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)